Last $93.83 USD
Change Today +0.40 / 0.43%
Volume 1.0M
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

alnylam pharmaceuticals inc (ALNY) Snapshot

Open
$92.56
Previous Close
$93.43
Day High
$95.36
Day Low
$91.56
52 Week High
12/8/14 - $111.49
52 Week Low
04/28/14 - $47.03
Market Cap
7.7B
Average Volume 10 Days
1.4M
EPS TTM
$-3.27
Shares Outstanding
82.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALNYLAM PHARMACEUTICALS INC (ALNY)

alnylam pharmaceuticals inc (ALNY) Related Businessweek News

View More BusinessWeek News

alnylam pharmaceuticals inc (ALNY) Details

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-CC5 for the treatment of complement-mediated diseases; ALN-AS1 for the treatment of hepatic porphyrias; ALN-PCS for the treatment of hypercholesterolemia; ALN-AAT for the treatment of AAT deficiency liver disease; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other programs. The company’s partner-based product development clinical and pre-clinical programs comprise ALN-RSV01 for the treatment of respiratory syncytial virus infection; ALN-VSP for the treatment of liver cancers; and ALN-HTT product candidate for the treatment of Huntington’s disease. It has strategic alliances and collaboration agreements with Genzyme Corporation; The Medicines Company; Kyowa Hakko Kirin Co., Ltd.; Cubist Pharmaceuticals, Inc.; Monsanto Company; Takeda Pharmaceutical Company Limited; F. Hoffmann-La Roche Ltd./Arrowhead Research Corporation; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; the Massachusetts Institute of Technology; Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics, Inc.; The University of British Columbia; Acuitas Therapeutics Inc.; Biogen Idec Inc.; Ascletis BioScience Co., Ltd.; Medtronic, Inc.; and CHDI Foundation, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

165 Employees
Last Reported Date: 02/20/14
Founded in 2002

alnylam pharmaceuticals inc (ALNY) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $669.5K
President and Chief Operating Officer
Total Annual Compensation: $500.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $252.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $450.0K
Compensation as of Fiscal Year 2013.

alnylam pharmaceuticals inc (ALNY) Key Developments

Alnylam Seeks Acquisitions

Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY) is seeking acquisitions. Alnylam is raising aggregate proceeds of approximately $450 million by issuing its common stock in a public offering. Alnylam intends to use the net proceeds from the offering for general corporate purposes including research and development expenses, including clinical trial costs, potential acquisitions of new businesses, technologies or products, working capital, capital expenditures and general and administrative expenses.

Alnylam Announces Encouraging Results from Phase I Hemophilia Study

Alnylam Pharmaceuticals, Inc. has announced encouraging results from its ongoing Phase I study of ALN-AT3, a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin, or AT, for the treatment of hemophilia and rare bleeding disorders, or RBD. Specifically, data were presented from the study's second dose cohort in hemophilia subjects (n=3), where subcutaneous administration of ALN-AT3 resulted in an up to 70% knockdown of AT. New results provide initial evidence for potential correction of the hemophilia phenotype associated with ALN-AT3 administration and AT knockdown. Specifically, ALN-AT3 administration resulted in an increase in thrombin generation of up to 334% and a marked improvement in whole blood clotting. In addition, the most advanced severe hemophilia A subject in the cohort has remained bleed free for 47 days without replacement factor prophylaxis. Finally, ALN-AT3 administration continues to be generally well tolerated.

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. Sign New Agreement to Develop RNA Therapeutics

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc., have signed a new agreement, extending their existing strategic partnership, for the development and commercialization of RNA therapeutics. This new agreement includes a cross-license of intellectual property (IP) on four disease targets, providing each company with exclusive RNA therapeutic license rights for two programs. The agreement also includes a non-exclusive technology IP cross-license, providing each company rights to certain of each other's technology advances for RNA therapeutics through April 2019.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $93.83 USD +0.40

ALNY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Galena Biopharma Inc $1.63 USD 0.00
Prosensa Holding NV $18.74 USD +0.06
Regulus Therapeutics Inc $19.15 USD +0.57
Silence Therapeutics PLC 222.00 GBp 0.00
Tekmira Pharmaceuticals Corp C$32.68 CAD -0.22
View Industry Companies
 

Industry Analysis

ALNY

Industry Average

Valuation ALNY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 191.8x
Price/Book 8.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 190.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit www.alnylam.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.